Visceral leishmaniasis: Novartis and DNDi to jointly develop a new oral drug
by Press Release from Outbreak News Today on (#4ZWB3)
Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world's leading parasitic killers. LXE408 is a first-in-class compound, discovered at Novartis with financial support from ["]
The post Visceral leishmaniasis: Novartis and DNDi to jointly develop a new oral drug appeared first on Outbreak News Today.